<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19751">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849769</url>
  </required_header>
  <id_info>
    <org_study_id>MR Tachy PAS</org_study_id>
    <nct_id>NCT02849769</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance (MR) Conditional Tachyarrhythmia Therapy Products Post-approval Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following product approval, further confirmation of the MR Conditional Tachyarrhythmia
      Therapy Systems sensing and detection performance post MRI exposure will be obtained by
      actively monitoring de-identified device data obtained through the Medtronic CareLink®
      Network.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the proportion of episodes with ≥ 5 seconds VF detection delay in the MR conditional tachyarrhythmia therapy system following MRI exposure.</measure>
    <time_frame>up to 5 years post-approval.</time_frame>
    <description>The primary objective will be analyzed and reported when 50 patients with a true VF episode following MR exposure have been identified</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10979</enrollment>
  <condition>Tachyarrhythmia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        MR conditional tachyarrhythmia therapy system enrolled in the Medtronic CareLink® Network
        (CL) will be used to prospectively assess spontaneous Ventricular Fibrillation (VF)
        episode detection following MRI exposure.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MR conditional tachyarrhythmia therapy system enrolled in the Medtronic CareLink®
             Network (CL) will be used to prospectively assess spontaneous Ventricular
             Fibrillation (VF) episode detection following MRI exposure.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 28, 2016</lastchanged_date>
  <firstreceived_date>July 27, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
